Flucloxacillin Intravenous Dosing for Methicillin-Susceptible Staphylococcus aureus Infections
For methicillin-susceptible Staphylococcus aureus (MSSA) infections, flucloxacillin should be administered at 1-2 g every 4 hours intravenously in adults, with pediatric dosing at 50 mg/kg/dose every 6 hours, though emerging evidence suggests continuous infusion at 8-12 g/24 hours may provide superior pharmacodynamic target attainment. 1
Adult Dosing Regimens
Standard Intermittent Dosing
- 1-2 g IV every 4 hours for serious staphylococcal infections including necrotizing skin and soft tissue infections 1
- This translates to 6-12 g total daily dose divided into 6 doses
- Infusion time: typically administered as short infusions over 30 minutes to 1 hour
Continuous Infusion (Preferred for Severe Infections)
- 8-12 g/24 hours as continuous infusion after an initial loading dose 2, 3
- Continuous infusion of 8 g/24 hours achieves serum concentrations of 8 to >40 mg/L 3
- For aggressive pharmacodynamic targets (100% time above MIC), 12 g/24 hours continuous infusion is recommended 2
- This approach maintains more consistent drug levels above the MIC, which is critical for beta-lactam efficacy 4
Clinical evidence strongly supports continuous infusion: A study of 20 patients with serious MSSA sepsis (including endocarditis and osteomyelitis) treated with continuous-infusion flucloxacillin 8-12 g/day showed 82% clinical and microbiological cure at long-term follow-up 3
Pediatric Dosing
Standard Dosing (Beyond Neonatal Period)
- 50 mg/kg/dose IV every 6 hours for serious staphylococcal infections 1
- Maximum single dose should not exceed adult dosing
Neonatal Dosing
- 25 mg/kg every 4 hours for all neonates initially, regardless of gestational or postnatal age 5
- This aggressive initial dosing is based on pharmacokinetic studies showing that standard regimens (25-50 mg/kg every 8-12 hours) failed to achieve effective plasma concentrations in 31% of neonates 5
- After pathogen isolation, if oxacillin-sensitive coagulase-negative staphylococci are identified, reduce to 10 mg/kg every 6 hours 5
Renal Dose Adjustment
Critical caveat: Current dosing guidelines for flucloxacillin during renal replacement therapy require revision based on recent evidence 6
Patients with Normal Renal Function
- No adjustment needed
- Renal clearance is approximately 5.37 L/h with nonrenal clearance of 2.73 L/h 4
Patients on Continuous Renal Replacement Therapy (CRRT)
- Start with 4 g/24 hours continuous infusion and adjust based on therapeutic drug monitoring (TDM) 6
- A case report demonstrated that standard high-dose regimens (9-12 g/24h) resulted in extremely high total (up to 299.8 mg/L) and unbound (up to 155.1 mg/L) concentrations during CVVH, requiring dose reduction to 3 g/24h 6
- Mandatory TDM is essential in this population to prevent toxicity while maintaining efficacy 6
Patients with Hypoalbuminemia
- Standard intermittent dosing is likely insufficient 2
- Continuous infusion of 8 g/24 hours minimum is recommended 2
- Flucloxacillin is 95-97% protein-bound; hypoalbuminemia increases unbound drug but also increases volume of distribution 2-fold 2
- Unbound concentrations after 2 g bolus fall below 1 mg/L within 4 hours, inadequate for MSSA with MIC = 2 mg/L 2
Treatment Duration
Duration depends on infection type and source control:
- Uncomplicated bacteremia: 14 days minimum after first negative blood culture 7
- Endocarditis: 4-6 weeks depending on valve involvement 7
- Osteomyelitis/vertebral infections: 6-8 weeks minimum 3
- Deep abscesses: Until clinical resolution plus 2-4 weeks 3
The mean duration in the continuous infusion study was 29 days (range 4-60 days) for serious MSSA sepsis 3
Pharmacodynamic Targets
Beta-lactam efficacy correlates with time above MIC (T>MIC) rather than peak concentrations 2, 4:
- Minimum target: 50% of dosing interval with free drug concentration >MIC 4
- Optimal target: 100% of time >MIC for serious infections 2
- For MSSA with MIC ≤1 mg/L, continuous infusion of 6 g/day achieves 86-90% probability of target attainment 4
- For more aggressive targets (4-5× MIC), 12 g/24h continuous infusion is required 2
Contraindications and Precautions
Absolute Contraindications
- Known hypersensitivity to flucloxacillin or other penicillins
- History of flucloxacillin-associated hepatotoxicity or cholestatic jaundice
Relative Contraindications and Monitoring
- Hepatic dysfunction: Flucloxacillin can cause cholestatic hepatitis; monitor liver enzymes weekly
- Penicillin allergy: For non-anaphylactic reactions, cefazolin 1 g IV every 8 hours (adults) or 33 mg/kg/dose every 8 hours (pediatrics) is an alternative 1
- Pregnancy/lactation: Generally considered safe but use clinical judgment
Therapeutic Drug Monitoring
- Strongly recommended in critically ill patients, those with renal dysfunction, hypoalbuminemia, or on CRRT 6, 2
- Target total plasma concentrations: 20-40 mg/L for continuous infusion 3
- Target unbound concentrations: maintain >4× MIC (typically >8 mg/L for MSSA) 2
- Toxic threshold: total concentrations >200 mg/L 5
Key Clinical Pitfalls
Underdosing in critically ill patients: Standard intermittent dosing often fails to maintain adequate concentrations in patients with hypoalbuminemia or increased volume of distribution 2
Overdosing in renal failure: Patients on CRRT can accumulate dangerously high levels with standard dosing; start low and use TDM 6
Ignoring protein binding: Total drug concentrations can be misleading; unbound concentrations determine efficacy and should guide dosing in hypoalbuminemic patients 2
Inadequate neonatal dosing: Standard neonatal regimens fail in nearly one-third of patients; more frequent dosing (every 4 hours) is necessary 5
Premature de-escalation: Ensure adequate source control and complete treatment duration, as S. aureus bacteremia has high rates of metastatic infection (>33%) and mortality (15-30%) 7